Joan Seoane

Joan Seoane

Vall d'Hebron Institut d'Oncologia

Life & Medical Sciences

Preclinical and Translational Research program Director at the Vall d'Hebron Institute of Oncology (VHIO) within the Vall d'Hebron Hospital since 2011. In 1998, he obtained his PhD from the University of Barcelona. Previously, in 1993, he obtained his BSc degree in Chemistry. Joan joined the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York as a post-doctoral fellow in 1998 (first as a Research Fellow and then Research Associate since 2001). He was appointed ICREA Research Professor in 2004 and joined VHIO. In 2008, he was the recipient of a European Research Council (ERC) grant. He obtained two ERC Proof of Concept grants (2011, 2013). In 2008, he became Board member of the European Association of Cancer Research (EACR) and Associate Prof. at Universitat Autònoma de Barcelona. In 2012, founded Mosaic Biomedicals as a spin-off company from his lab and, in 2013, he was the recipient of the Dr. Josef Steiner Award. In 2016, he became Secretary General of the EACR.

Research interests

Our main objective is to understand the molecular mechanisms involved in the initiation and progression of cancer. Specifically, our research is focused on the study of brain tumours, including glioma and brain metastasis. Both glioblastoma (the most aggressive form of glioma) and brain metastasis are dismal diseases with limited therapeutic options. The understanding of the molecular mechanisms that govern these types of cancer is required in order to design rational, specific and successful therapeutic approaches.

Selected publications

- Gargini R*, Segura-Collar B*, Herránz B, Garcia-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A,  Castro MG, García-Escudero R, Ávila J & Sánchez-Gómez P  2020, 'The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas', Sci Transl Med, 12(527).  

- Le Rhun E, Seoane J, Salzet M, Soffietti R & Weller M 2020, 'Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system', Cancer Letters, 480, 24 - 28.

- Seoane J 2020, 'Immunotherapy research: today’s science is tomorrow’s medicine', The Innovation Platform 1:122-123

- Ciardiello D, Elez ME, Tabernero J & Seoane J 2020, 'Clinical development of therapies targeting TGFβ: current knowledge and future perspectives', Annals of Oncology, 31 (10) 1336 - 1349.

- Jiménez, I, Carabia J, Bobillo S, Palacio C, Abrisqueta P, Pagès C, Nieto JC, Castellví J, Martínez‑Ricarte F, Escoda L, Perla C,  Céspedes-Torrez DH, Boix J, Purroy N, Puigdefàbregas L, Seoane J, Bosch F & Crespo M 2020, 'Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition'. J of Neuro-Oncology, 149, pp 13–25.

- Escudero L, Martínez-Ricarte F, Seoane J. 2020 'Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies'. Current Opinion Neurology. 33(6):736-741   

- Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S & Seoane J 2020, 'Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma', Nature Comm. 11(1):5376.

Selected research activities

Completion of the Phase 1 clinical trial in cancer of MSC1, the first compound from Mosaic Biomedicals, company founded by Joan Seoane